Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized multicenter study comparing infliximab vs cyclophosphamide in severe Behçet's disease
2017-002264-41Phase 2
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Behçet's disease (BD) comparing Infliximab (Remicade) arm with Cyclophosphamide arm (2 arms). Primary endpoint: Complete clinical response at week 22.
02
Drugs
infliximabcyclophosphamide
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2017-002264-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002264-41.